


## **Technology Advisory Committee C Interests Register**

Topic: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell


lymphoma after 2 or more systemic therapies (CDF Review of TA559) [ID3980]

Publication Date: 28/02/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Michael Chambers	Committee Member	Financial	Mr Chambers has co- ordinated a training programme with the University of Utrecht for Roche (comparator company) on Real World Evidence, which did not involve specific consideration of Roche's products. He has participated in an advisory panel for Pfizer (comparator company) in an unrelated disease area (prostate cancer).	N/A	16/08/2022	N/A	It was agreed his declarations would not prevent Mr Chambers from participating in discussions on this appraisal.
Dr Richard Nicholas	Committee Member	Financial	Dr Nicholas has carried out paid advisory boards with Roche (comparator company) in an unrelated area (multiple sclerosis).	N/A	22/08/2022	N/A	It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal.
Stella O'Brien	Committee Member	Personal	Ms O'Brien has joined the Genetic Alliance UK Working Group for Patient and Public Involvement and Engagement for Advanced therapy	N/A	06/09/2022	N/A	It was agreed her declaration would not prevent Ms O'Brien from participating in



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			medicinal products (ATMPs). It is the largest alliance of organisations supporting people with genetic, rare, and undiagnosed conditions in the UK.				discussions on this appraisal.
Dr Graham Collins	Clinical expert	Financial	Dr Collins has received honoraria for speaker and consultancy work from Kite/Gilead and Novartis.	N/A	08/07/2022	N/A	It was agreed his declaration would not prevent Dr Collins from providing expert advice to the committee.
Dr Keith Wilson	Clinical expert	Indirect	Dr Wilson has received travel grants from Kite/Gilead.  He has attended Advisory Boards and Speakers' Bureau and received honoraria from Kite/Gilead, Novartis and Celgene.  He has received Institutional Research Grants – The SWBMT Programme is currently in receipt of funding from Kite/Gilead under its Fellowship Scheme and has a Kite Fellow who oversees the rehabilitation programme.	N/A	11/07/2022	N/A	It was agreed his declarations would not prevent Dr Wilson from providing expert advice to the committee.



Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			Dr Wilson is currently in discussions with Kite/Gilead regarding a possible research collaboration.				
			He is a member of the Industry Advisory Group of Cell and Gene Therapy Catapult which advises the UK Government on issues pertinent to adoption of ATMPs.		06/09/2022		